Unknown

Dataset Information

0

A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.


ABSTRACT: PURPOSE:Irinotecan, in combination with leucovorin/5-fluorouracil (FU) or with cisplatin, is known to be active for treating advanced gastric cancer (AGC). This pilot study evaluated a novel three-drug combination of irinotecan, leucovorin/FU and cisplatin as a first-line treatment of AGC. The primary endpoint was to assess the feasibility in anticipation of conducting a larger phase II study. MATERIALS AND METHODS:Chemotherapy-naive AGC patients received irinotecan 150 mg/m(2) on day 1, and leucovorin 200 mg/m(2) and a 22-h infusion of FU 1000 mg/m(2) on days 1 and 2. Cisplatin 30 mg/m(2) was administered on day 2. Treatment was repeated every 2 weeks until disease progression or unacceptable toxicity. RESULTS:Of the 17 eligible patients, two patients had an ECOG performance status of 2 and their median age was 48 years (range: 31 to 69). A total of 117 chemotherapy cycles were delivered (median: 6, range: 1 to 12). The causes of treatment discontinuation were disease progression in 9 patients (53%), refusal (35%) and toxicity (12%). Although grade 3 or 4 neutropenia (41% of patients) was the major toxicity that required dose adjustments, only one episode of febrile neutropenia occurred. Grade 3 or 4 nausea and vomiting, diarrhea and fatigue were observed in 35%, 35% and 29% of patients, respectively. None of the patients died of toxicity during treatment. Of the 16 patients who were evaluable for response, 7 (44%) experienced a partial response. CONCLUSION:This novel multi-drug combination was tolerated well in patients with AGC. Based on the encouraging efficacy and tolerability, a randomized phase II study is ongoing in this disease setting.

SUBMITTER: Park SH 

PROVIDER: S-EPMC2741674 | biostudies-literature | 2006

REPOSITORIES: biostudies-literature

altmetric image

Publications

A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.

Park Se Hoon SH   Jeon Soo Yeon SY   Ko Kwang Il KI   Nam Eunmi E   Bang Soo-Mee SM   Cho Eun Kyung EK   Shin Dong Bok DB   Lee Jae Hoon JH   Lee Woon Ki WK   Chung Min M  

Cancer research and treatment 20060630 3


<h4>Purpose</h4>Irinotecan, in combination with leucovorin/5-fluorouracil (FU) or with cisplatin, is known to be active for treating advanced gastric cancer (AGC). This pilot study evaluated a novel three-drug combination of irinotecan, leucovorin/FU and cisplatin as a first-line treatment of AGC. The primary endpoint was to assess the feasibility in anticipation of conducting a larger phase II study.<h4>Materials and methods</h4>Chemotherapy-naive AGC patients received irinotecan 150 mg/m(2) on  ...[more]

Similar Datasets

| S-EPMC8764657 | biostudies-literature
2011-06-01 | E-GEOD-14208 | biostudies-arrayexpress
| S-EPMC5117585 | biostudies-literature
2011-06-01 | GSE14208 | GEO
| S-EPMC7983461 | biostudies-literature
| S-EPMC3137420 | biostudies-literature
| S-EPMC2698019 | biostudies-literature
| S-EPMC2990583 | biostudies-literature
| S-EPMC7848150 | biostudies-literature
| S-EPMC3041770 | biostudies-literature